“We are thrilled to announce this major milestone in our partnership with Irvine Labs, as they have now received their import permit for 3 kg of psilocybin raw materials,” said Todd Shapiro, CEO and Director of Red Light Holland. “This advancement comes at a significant time as we’ve seen growing institutional support for psilocybin research, including from the new U.S. Surgeon General and the Department of Veterans Affairs, which we applaud. With the Controlled Substances Import Permit secured, we can now ship our psilocybin raw materials from our Netherlands farm to Irvine’s California Lab to begin development of extended shelf-life microdosing capsules. This is another critical step in our mission: from underground to mainstream, and as a Company we are very proud of our overall progress and focus on standardization of naturally occurring psilocybin as our R&D continues with the overall goal of access and making a positive impact.”

Shaun Land, President of Irvine Labs, added, “Receiving the Controlled Substances Import Permit represents the final regulatory hurdle in our collaboration with Red Light Holland, at this stage. We are now ready to receive the 3 kg of raw materials from the Netherlands and begin our work. We have extensive experience working with naturally derived pharmaceutical ingredients and are excited to support Red Light Holland’s microdosing program with our expertise in manufacturing and compliance, aiming to extend these innovative products stability and shelf life.”

Red Light and Irvine Labs combined goal is to develop a commercialized and standardized product from the Company’s psilocybin truffles farm grown truffles that can be legally exported to emerging markets and used in government-funded pilot programs and clinical trials within the United States.

About Irvine Labs

Irvine Labs was established in 1997. Since 2013, Irvine Labs has had a significant investment in medical research and development through its Pharmaceutical Biotechnology Division with a focus on natural medicines, including cannabis, cannabinoids, psilocybin, herbs and other sources of natural medicines. Irvine Labs is licensed for Prescription and Over-the-Counter (OTC) drug manufacturing by the California Department of Public Health (CDPH). Irvine Labs is a DEA Schedule 1 Bulk drug manufacturer, importer and exporter (including marijuana, THC, extracts, psilocybin, psilocin, DET, DMT, LSD, Peyote and Mescaline), and Schedule 1-5 testing lab.

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co

Forward-Looking Statements and Cautionary Note

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events.

The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s performance, business objectives and milestones and the anticipated timing thereof, and costs in connection with, the execution or achievement of such objectives and milestones, including its plans to continue seeking legal opportunities to increase responsible access to natural psilocybin around the world and Irvine lab’s development of the Company’s psilocybin; the Company and the Company’s partners to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the expectations with respect to the Company’s planned psilocybin import following Irvine Labs’ successful receipt of its 2025 psilocybin DEA quota and pending import permit approval; the Company’s continued commitment towards ensuring legal, responsible access to Red Light’s standardized natural psilocybin products; the Company’s commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs Inc. and the research project to develop a process for the commercial manufacture of microdosing capsules derived from the Company’s psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; the Company’s ability to extract and expand access to psilocybin products; the Company’s ability to successfully land the 3K shipment in the United States of America, the Company’s ability to control the risk that the Controlled Substances Import Permit could become null and void and/or reversed; the Company’s goals to standardize and sell advanced microdosing products to emerging markets or the United States for clinical trials or government funded programs; and the Company’s ability to scalable production of high-quality, and approved microdoing capsules with extended shelf life via Irvine Labs ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the United States or around the world.

Forward-Looking information in this press release are based on certain assumptions and expected future events, namely: the Company’s ability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company’s partners’ abilities, including Irvine Labs to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company’s ability to realize its plans for its planned psilocybin imports following Irvine Labs’ successful receipt of its 2025 psilocybin DEA quota and pending import permit approval; the Company’s ability for its continued commitment towards ensuring legal, responsible access to Red Light’s standardized natural psilocybin products; the Company’s ability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs and their research project to develop a process for the commercial manufacture of natural-source microdoing capsules derived from the Company’s psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; the ability to extract and expand access to psilocybin products; the Company’s ability to successfully land the shipment in the United States of America, the Company’s goals to standardize and sell advanced microdosing products to emerging markets or the United States for clinical trials or government funded programs; the Company’s ability to control the risk that the Controlled Substances Import Permit could become null and void and/or reversed; and the Company’s ability to have scalable production of high-quality, microdosing capsules with extended shelf life for Global Distribution and The Company’s ability to import their products into the United States and eventually the Companys ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the USA or around the world.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company’s partners’ inabilities, including Irvine Labs, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company’s inability to realize upon its plans for its planned psilocybin import despite Irvine Labs’ successful receipt of its 2025 psilocybin DEA quota; delays or issues with the import permit process; the Company’s inability to maintain its commitment towards ensuring legal, responsible access to Red Light’s standardized natural psilocybin products; the Company’s inability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs; and The Company’s ability to expand and extract access to psilocybin products.

The Company cannot make medical claims and is purely in a R&D phase with its partners Irvine Labs Inc.

Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-Looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252904